Aktuellt
SENASTE
Redeye provides a research update on Lipum following the Q1 report published by the company earlier today. We make some slight adjustments to our OPEX estimates following slightly lower reported R&D costs than expected. However, we reiterate our previous fair value range (SEK5 – SEK35) with a base case valuation of SEK22 as we continue to see significant upside potential in the stock.
LÄS MER
